-
Je něco špatně v tomto záznamu ?
Electrocardiographic Predictors of Torsadogenic Risk During Dofetilide or Sotalol Initiation: Utility of a Novel T Wave Analysis Program
A. Sugrue, V. Kremen, B. Qiang, SH. Sheldon, CV. DeSimone, Y. Sapir, BL. Striemer, P. Brady, SJ. Asirvatham, MJ. Ackerman, P. Friedman, PA. Noseworthy,
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
ProQuest Central
od 1999-03-01 do Před 1 rokem
Medline Complete (EBSCOhost)
od 2011-02-01 do Před 1 rokem
Health & Medicine (ProQuest)
od 1999-03-01 do Před 1 rokem
- MeSH
- antiarytmika škodlivé účinky MeSH
- elektrokardiografie metody MeSH
- fenethylaminy škodlivé účinky MeSH
- lidé středního věku MeSH
- lidé MeSH
- prediktivní hodnota testů * MeSH
- senioři MeSH
- software * MeSH
- sotalol škodlivé účinky MeSH
- studie případů a kontrol MeSH
- sulfonamidy škodlivé účinky MeSH
- torsades de pointes chemicky indukované prevence a kontrola MeSH
- Check Tag
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
INTRODUCTION: Initiation of class III anti-arrhythmic medications requires telemetric monitoring for ventricular arrhythmias and QT prolongation to reduce the risk of torsades de pointes (TdP). Heart rate-corrected QT interval (QTc) is an indicator of risk, however it is imperfect, and subtle abnormalities of repolarization have been linked with arrhythmogenesis. PURPOSE: Identification of electrocardiographic predictors of torsadogenic risk through the application of a novel T wave analysis tool. METHODS: Among all patients admitted to Mayo Clinic for initiation of dofetilide or sotalol, we identified 13 cases who developed drug-induced TdP and 26 age and sex matched controls that did not develop TdP. The immediate pre-TdP ECG of those with TdP was compared to the last ECG performed prior to hospital discharge in controls using a novel T wave program that quantified subtle changes in T wave morphology. RESULTS: The QTc and 12 T wave parameters successfully distinguished TdP cases from controls. The top performing parameters were the QTc in lead V3 (mean case vs control 480 vs 420 msec, p < 0.001, r = 0.72) and T wave right slope in lead I (mean case vs control -840.29 vs -1668.71 mV/s, p = 0.002, r = 0.45). The addition of T wave right slope to QTc improved prediction accuracy from 79 to 88 %. CONCLUSION: Our data demonstrate that, in addition to QTc, the T wave right slope is correlated strongly with TdP risk. This suggests that a computer-based repolarization measurement tool that integrates additional data beyond the QTc may identify patients with the greatest torsadogenic potential.
Ben Gurion University of the Negev Beersheba Israel
Department of Cardiology University of Michigan Ann Arbor MI USA
Department of Internal Medicine Mayo Clinic Rochester MN USA
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16028176
- 003
- CZ-PrNML
- 005
- 20161021104358.0
- 007
- ta
- 008
- 161005s2015 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s10557-015-6619-0 $2 doi
- 024 7_
- $a 10.1007/s10557-015-6619-0 $2 doi
- 035 __
- $a (PubMed)26411977
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Sugrue, Alan $u Department of Internal Medicine, Mayo Clinic, Rochester, MN, USA.
- 245 10
- $a Electrocardiographic Predictors of Torsadogenic Risk During Dofetilide or Sotalol Initiation: Utility of a Novel T Wave Analysis Program / $c A. Sugrue, V. Kremen, B. Qiang, SH. Sheldon, CV. DeSimone, Y. Sapir, BL. Striemer, P. Brady, SJ. Asirvatham, MJ. Ackerman, P. Friedman, PA. Noseworthy,
- 520 9_
- $a INTRODUCTION: Initiation of class III anti-arrhythmic medications requires telemetric monitoring for ventricular arrhythmias and QT prolongation to reduce the risk of torsades de pointes (TdP). Heart rate-corrected QT interval (QTc) is an indicator of risk, however it is imperfect, and subtle abnormalities of repolarization have been linked with arrhythmogenesis. PURPOSE: Identification of electrocardiographic predictors of torsadogenic risk through the application of a novel T wave analysis tool. METHODS: Among all patients admitted to Mayo Clinic for initiation of dofetilide or sotalol, we identified 13 cases who developed drug-induced TdP and 26 age and sex matched controls that did not develop TdP. The immediate pre-TdP ECG of those with TdP was compared to the last ECG performed prior to hospital discharge in controls using a novel T wave program that quantified subtle changes in T wave morphology. RESULTS: The QTc and 12 T wave parameters successfully distinguished TdP cases from controls. The top performing parameters were the QTc in lead V3 (mean case vs control 480 vs 420 msec, p < 0.001, r = 0.72) and T wave right slope in lead I (mean case vs control -840.29 vs -1668.71 mV/s, p = 0.002, r = 0.45). The addition of T wave right slope to QTc improved prediction accuracy from 79 to 88 %. CONCLUSION: Our data demonstrate that, in addition to QTc, the T wave right slope is correlated strongly with TdP risk. This suggests that a computer-based repolarization measurement tool that integrates additional data beyond the QTc may identify patients with the greatest torsadogenic potential.
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a antiarytmika $x škodlivé účinky $7 D000889
- 650 _2
- $a studie případů a kontrol $7 D016022
- 650 _2
- $a elektrokardiografie $x metody $7 D004562
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a fenethylaminy $x škodlivé účinky $7 D010627
- 650 12
- $a prediktivní hodnota testů $7 D011237
- 650 12
- $a software $7 D012984
- 650 _2
- $a sotalol $x škodlivé účinky $7 D013015
- 650 _2
- $a sulfonamidy $x škodlivé účinky $7 D013449
- 650 _2
- $a torsades de pointes $x chemicky indukované $x prevence a kontrola $7 D016171
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Kremen, Vaclav $u Czech Institute of Informatics, Robotics, and Cybernetics, Czech Technical University in Prague, Prague, Czech Republic. Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA.
- 700 1_
- $a Qiang, Bo $u Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA.
- 700 1_
- $a Sheldon, Seth H $u Department of Cardiology, University of Michigan, Ann Arbor, MI, USA.
- 700 1_
- $a DeSimone, Christopher V $u Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA.
- 700 1_
- $a Sapir, Yehu $u Ben Gurion University of the Negev, Beersheba, Israel.
- 700 1_
- $a Striemer, Bryan L $u Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA.
- 700 1_
- $a Brady, Peter $u Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA.
- 700 1_
- $a Asirvatham, Samuel J $u Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA. Division of Pediatric Cardiology, Department of Pediatrics and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA. $7 gn_A_00009398
- 700 1_
- $a Ackerman, Michael J $u Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA. Division of Pediatric Cardiology, Department of Pediatrics and Adolescent Medicine, Mayo Clinic, Rochester, MN, USA. Windland Smith Rice Sudden Death Genomics Laboratory, Department of Molecular Pharmacology & Experimental Therapeutics, Mayo Clinic, Rochester, MN, USA. $7 gn_A_00001006
- 700 1_
- $a Friedman, Paul $u Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA.
- 700 1_
- $a Noseworthy, Peter A $u Division of Cardiovascular Diseases, Department of Internal Medicine, Mayo Clinic, 200 First Street SW, Rochester, MN, USA. noseworthy.peter@mayo.edu.
- 773 0_
- $w MED00001057 $t Cardiovascular drugs and therapy sponsored by the International Society of Cardiovascular Pharmacotherapy $x 1573-7241 $g Roč. 29, č. 5 (2015), s. 433-41
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26411977 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20161005 $b ABA008
- 991 __
- $a 20161021104806 $b ABA008
- 999 __
- $a ok $b bmc $g 1166490 $s 952806
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2015 $b 29 $c 5 $d 433-41 $i 1573-7241 $m Cardiovascular drugs and therapy $n Cardiovasc Drugs Ther $x MED00001057
- LZP __
- $a Pubmed-20161005
